HVE Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
Strong TTM ProfitabilityVery high trailing-twelve-month margins and a sharp earnings rebound indicate durable core earnings power from Innoviva’s asset-heavy model. High margins provide structural capacity to fund investments, buybacks or shareholder returns and absorb partner sales variability over months.
Improved Balance Sheet FlexibilityMeaningful equity growth and modest current leverage enhance financial flexibility for acquisitions, asset monetizations and capital support to portfolio companies. A stronger balance sheet lowers refinancing risk and supports multi-quarter strategic deployment of cash.
Consistent Positive Cash GenerationConsistently positive operating and free cash flow across reported periods shows the company converts earnings to cash reliably. This persistent cash generation supports recurring distributions, opportunistic investments and reduces dependence on external financing over the medium term.
Bears Say
Earnings And Cash VolatilityWide year-to-year swings in profitability and choppy free cash flow growth undermine predictability of core cash returns. Volatility complicates forecasting for asset monetization and capital allocation, increasing reliance on management judgment across multiple quarters.
Concentration On GSK RoyaltiesA material reliance on royalties tied to a partner’s respiratory product sales concentrates revenue and cash risk. Product lifecycle, mix shifts or partner commercial performance can materially alter Innoviva’s cash flows for many quarters, limiting diversification of durable income sources.
Board Turnover And Related-Party FocusRecent board departures tied to executives’ focus on Syndeio and ongoing strategic/financial support create potential related-party exposure and management distraction. Over several quarters this can influence capital allocation, strategic priorities, and governance consistency.
Innoviva News
HVE FAQ
What was Innoviva’s price range in the past 12 months?
Currently, no data Available
What is Innoviva’s market cap?
Innoviva’s market cap is CHF1.31B.
When is Innoviva’s upcoming earnings report date?
Innoviva’s upcoming earnings report date is Jul 29, 2026 which is in 26 days.
How were Innoviva’s earnings last quarter?
Innoviva released its earnings results on May 06, 2026. The company reported $1.796 earnings per share for the quarter, beating the consensus estimate of $0.315 by $1.48.
Is Innoviva overvalued?
According to Wall Street analysts Innoviva’s price is currently Undervalued.
Does Innoviva pay dividends?
Innoviva does not currently pay dividends.
What is Innoviva’s EPS estimate?
Innoviva’s EPS estimate is 0.35.
How many shares outstanding does Innoviva have?
Currently, no data Available
What happened to Innoviva’s price movement after its last earnings report?
Innoviva reported an EPS of $1.796 in its last earnings report, beating expectations of $0.315. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Innoviva?
Currently, no hedge funds are holding shares in CH:HVE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Innoviva Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
13.04%
12-Months-Change
Fundamentals
Return on Equity
47.59%
Trailing 12-Months
Asset Growth
46.41%
Trailing 12-Months
Company Description
Innoviva
Innoviva, Inc. functions as a pharmaceutical company, concentrating on the worldwide creation and marketing of medical treatments. Its current product lineup prominently includes several once-daily combination therapies: RELVAR/BREO ELLIPTA, which integrates vilanterol (a long-acting beta2 agonist, or LABA) with fluticasone furoate (an inhaled corticosteroid, or ICS); ANORO ELLIPTA, a medication that pairs umeclidinium bromide (a long-acting muscarinic antagonist, or LAMA) with vilanterol (LABA); and TRELEGY ELLIPTA, a comprehensive treatment combining an ICS, LAMA, and LABA. The company has forged a key strategic alliance with Sarissa Capital Management LP. Moreover, Innoviva collaborates with Glaxo Group Limited under an agreement focused on the development and commercialization of daily LABA-based products designed to treat chronic obstructive pulmonary disease and asthma. Founded in 1996, the corporation was initially known as Theravance, Inc., before officially changing its name to Innoviva, Inc. in January 2016. Its primary operational base is situated in Burlingame, California.
HVE Stock 12 Month Forecast
Average Price Target
$27.90
Options Prices
Currently, No data available
---